CipA mediates complement resistance of *Acinetobacter baumannii* by formation of a Factor I-dependent quadripartite assemblage

Julia I. Ries^a, Marie Heß^a, Noura Nouri^a, Thomas A. Wichelhaus^a, Stephan Göttig^a, Franco H. Falcone^b, and Peter Kraiczy^a

^aInstitute of Medical Microbiology and Infection Control, University Hospital of Frankfurt, Goethe University Frankfurt, D-60596 Frankfurt, Germany

^bInstitute for Parasitology, Biomedical Research Center Seltersberg, Justus Liebig University Giessen, D-35392 Giessen, Germany

JIR, MH, and NN contributed equally to this work

Corresponding author: PK

Keywords

Acinetobacter baumannii, immune evasion, innate immunity, complement, serum resistance

Authors contributions:

- Designed research: JIR, MH, NN, FHF
- Performed research: JIR, MH, NN, SG, FHF, PK
- Contributed new reagents and analytic tools: TW, SG, FHF
- Analyzed data: JIR, MH, NN, FHF, SG, PK
- Wrote the paper: JIR, SG, FHF, PK

This PDF file includes:

Main Text

Figures 1 to 8

1 **Abstract**

2 Multidrug-resistant *Acinetobacter baumannii* is known to be one of the leading pathogens
3 that cause severe nosocomial infections. To overcome eradication by the innate immune
4 system during infection, *A. baumannii* developed a number of immune evasion strategies.
5 Previously, we identified CipA as a plasminogen-binding and complement-inhibitory protein.
6 Here we show that CipA strongly inhibits all three complement activation pathways and
7 interacts with key complement components C3, C3b, C4b, C5, Factor B, Factor D, and in
8 particular Factor I. CipA also targets function of the C5 convertase as cleavage of C5 was
9 impaired. Systematic screening of CipA variants identified two separate binding sites for C3b
10 and a Factor I-interacting domain located at the C-terminus. Structure predictions using
11 AlphaFold2 and binding analyses employing CipA variants lacking Factor I-binding capability
12 confirmed that the orientation of the C-terminal domain is essential for the interaction with
13 Factor I. Hence, our analyses point to a novel, Factor I-dependent mechanisms of
14 complement inactivation mediated by CipA of *A. baumannii*. Recruitment of Factor I by CipA
15 initiates the assembly of a quadripartite complex following binding of either Factor H or C4b-
16 binding protein to degrade C3b and C4b, respectively. Loss of Factor I binding in a CipA-
17 deficient strain, or a strain producing a CipA variant lacking Factor I-binding capability,
18 correlated with a higher susceptibility to human serum, indicating that recruitment of Factor
19 I enables *A. baumannii* to resist complement-mediated killing.

20

21 **Significance Statement**

22 The Gram-negative bacterium *Acinetobacter baumannii* causes severe nosocomial infections
23 and has developed various immune evasion strategies to overcome complement. The
24 mechanisms how *Acinetobacter baumannii* successfully circumvents complement-mediated

25 bacteriolysis are still poorly understood. Here, we show that the plasminogen-binding and
 26 complement inhibitory protein CipA terminates all three complement activation pathways.
 27 We describe a novel mechanism by which CipA cleaves the key complement components
 28 C3b and C4b in the presence of Factor H and C4b-binding protein by formation of a novel
 29 Factor I-dependent quadripartite complex. CipA, which has recently been successfully used
 30 for vaccination approaches, might represent an attractive target for the development of
 31 novel therapeutic interventions to block disorders with excessive hyperinflammatory
 32 complement activation.

33

34 **Introduction**

35 *Acinetobacter (A.) baumannii* is considered as an emerging opportunistic pathogen of clinical
 36 significance and known to be a major cause of hospital-acquired infections (1-3). Of
 37 particular global concern and urgent health threat is the emergence of carbapenem-resistant
 38 or even pandrug-resistant *A. baumannii* (CRAB) (4-6). In 2017, the World Health Organization
 39 (WHO) has prioritized CRAB as critical pathogen for which drug research and development
 40 are urgently needed (7). In addition to extensive antibiotic resistance, the capability of this
 41 pathogen to overcome innate immunity enable *A. baumannii* to successfully establish
 42 infection in the human host (8, 9).

43 Complement is a central pillar of innate immunity and plays an important part in the defense
 44 against invading microorganisms, for the crosstalk between with immune cells as well as for
 45 homeostasis (10, 11). Activation of the complement system is typically achieved by three
 46 canonical pathways: the classical, lectin, and alternative pathway (12, 13). Antibody-
 47 mediated activation of the classical pathway (CP) involves initial binding of the C1 complex,
 48 while recognition of specific carbohydrate signatures results in activation of the lectin

49 pathway (LP). The spontaneous activation of the key component C3, binding to cell surfaces
 50 or binding to properdin triggers the alternative pathway (AP). Binding of activated C3b to
 51 Factor B (FB) causes a change in the conformation that renders FB more accessible to
 52 cleavage by factor D (FD), thereby generating the soluble form of the C3 convertase of the
 53 AP. All three pathways converge into the assembly of the C3 convertases C3bBb of the AP or
 54 C4b2b of the CP and LP, respectively. Subsequent proteolytic cleavage of C3 into C3b and
 55 C3a by the formed C3 convertases leads to opsonization and flagging of invading
 56 microorganisms for phagocytosis with activated C3b molecules. Subsequent binding of C3b
 57 leads to the generation of the C5 convertases (C3bBb3b of the AP or C4b2b3b of the CP and
 58 LP) and thereby alters their substrate specificity toward C5. Cleavage of C5 into C5b and C5a
 59 initiates the terminal pathway by sequential binding of complement components C6, C7, C8,
 60 and multiple copies of C9 resulting in formation of the membrane attack complex (MAC).
 61 Finally, the integration of the pore-forming complex destabilizes the microbial membrane
 62 leading to killing of the intruding pathogen (12, 13).

63 To keep the activation of the complement system in check, all three pathways are tightly
 64 controlled by distinct complement regulatory proteins (12, 13). The assembly of the C3 and
 65 C5 convertases is controlled by soluble complement regulators such as Factor H (FH) or C4b-
 66 binding protein (C4BP). In circulation, FH and C4b-binding protein (C4BP) impairs the
 67 generation of these convertases by acting as cofactors for serine protease Factor I (FI)-
 68 mediated degradation of C3b and C4b (12, 13). Moreover, FI in solution exhibits a very low
 69 proteolytic activity toward C3b and C4b (14).

70 Several proteins have been described to contribute to complement resistance of
 71 *A. baumannii*, including AbOmpA (15), penicillin-binding protein-7/8 (PBP-7/8) (16), serine
 72 protease PKF (17), elongation factor Tuf (18), phospholipase D (19), surface antigen protein

73 SurA1 (20), trimeric autotransporter Ata (21) as well as CipA (22), all of which are considered
74 to play important roles in pathogenesis (23). Previously, we identified CipA as a complement
75 inhibitory and plasminogen-binding molecule enabling *A. baumannii* to cross endothelial
76 monolayers and to degrade the key complement component C3b by conversion of
77 plasminogen to active plasmin (22). Of relevance, we also demonstrated that CipA also
78 directly inhibits the AP, irrespective of its plasminogen-binding activity, and thus contributes
79 to complement resistance of *A. baumannii*.

80 In this study, we sought to elucidate the underlying molecular principles of complement
81 resistance mediated by CipA. Functional analyses revealed that CipA inhibits complement at
82 the C3 and C5 activation level and impairs the function of the C5 convertases. CipA variants
83 lacking FI binding capability completely lose their complement inactivating capacity
84 indicating that interaction of CipA with FI is crucial for complement inhibition. Here we also
85 show that a CipA-deficient strain, or a strain producing a CipA variant lacking FI-binding
86 capability displayed a significantly higher susceptibility of *A. baumannii* to complement-
87 mediated killing. Our analyses revealed a novel mode of complement inactivation mediated
88 by CipA which involves the formation of a FI-dependent quadripartite-ordered assemblage
89 consisting of CipA-FI-C3b-FH and CipA-FI-C4b-C4BP, respectively.

90

91 **Results**

92 **The C-terminal region of CipA is responsible for the inactivation of the alternative and** 93 **classical pathway**

94 Recently, we showed that CipA of *A. baumannii* inactivates complement at early activation
95 steps but did not impact the activation of the terminal pathway (22), e.g. by inhibiting the
96 assembly of the MAC as previously described for different bacterial proteins (24-26). To gain

deeper insights into the molecular principles by which CipA terminates complement activation and to narrow down the complement-interacting region(s), a number of single, double, and multi-point mutants as well as diverse deletion CipA variants were generated for functional analyses (**Fig. 1**). The inhibitory potential of CipA variants on the alternative and the classical pathway was assessed by preincubation of the purified proteins with different amounts of normal human serum (NHS) before adding to prepared microtiter plates to initiate complement activation. Deletion of 10 C-terminal amino acids (CipA Δ E360-K369) was sufficient to achieve a complete loss of the complement inactivating capacity of CipA on the AP and CP (**Fig. 1B and C**). However, CipA deletion variants CipA Δ A352-K369 and CipA Δ E360-K369 significantly enhanced activation of the CP (**Fig. 1C**). Substitutions or deletions of single or multiple amino acids did not affect or marginally affected the inhibitory potential of CipA on both pathways (**Fig. 1E and F**). CipA Δ Q19-Q144 carrying a N-terminal deletion of 144 amino acids retained complement inhibitory activity on both the AP and CP (**Fig. 1B and D**). This indicates that the whole C-terminal region (residues E360 to K369) but neither single amino acid residues nor electrostatic forces play a prominent role in complement inactivation as previously shown for variant CipA K365A-K369A that lose plasminogen-binding property (22).

To further determine the inhibitory potency of CipA on the AP, increasing concentrations of the protein were applied for ELISA. CipA showed strong dose-dependent, inhibitory properties on the AP with a calculated IC_{50} of 12.5 nM (**Fig. S1A and S1B**). This strong inhibition on the AP was also observed for the extracellular fibrinogen-binding protein (Efb) and its C-terminal fragment Efb-C of *Staphylococcus aureus* (**Fig. S1C and S1D**) (27).

CipA of *A. baumannii* bound different complement components

The inhibitory capacity of CipA on the AP and CP suggests an interaction with various complement components. Employing ELISA, CipA bound C3, C3b, C4b and C5, but did not interact with complement regulator FH (**Fig. 2**). Although statistically significant, binding of C3c, FB, and FD to CipA was less pronounced. Further analyses of the CipA interacting complement components revealed a dose-dependent binding for C3b, C4b, and C5 (**Fig. S2**). As CipA appears to preferentially bind to C3b, we sought to narrow down the C3b-interacting region within CipA by comparing different CipA variants (**Fig. S3**). Unexpectedly, none of the modifications introduced in CipA showed a significant reduction in C3b binding. However, larger deletions at the N- and C-terminus displayed an inverse effect resulting in an increased C3b binding, in particular when variants CipA Δ Q19-Q144, CipA Δ L154-K369, and CipA Δ Q291-K369 were employed (**Fig. S3B**). In addition, minor changes of the C-terminus also did not affect C3b binding (**Fig. S3D and S3E**). These findings suggest that multiple regions within CipA are involved in binding of C3b.

Interaction of CipA with the *in vitro* generated C3 convertase of the AP

Interaction of CipA with C3B and FB raises the possibility that CipA inhibits complement activation at the level of C3b by impeding the generation of the C3 convertase. In an initial attempt, a Ni^{2+} -dependent C3bB proconvertase was assembled on microtiter plates as described (28, 29). A stable C3bB proconvertase could be generated *in vitro* upon detection of FB bound to C3b (**Fig. S4A**). In addition, dose-dependent binding of FB to C3b could be demonstrated by employing increasing concentrations of FB (**Fig. S4B**). Binding of FB to C3b was neither blocked when CipA was immobilized on microtiter plates prior adding C3b and FB (**Fig. S4C**) nor when CipA was added sequentially or in combination with FB (competitive)

to C3b coated plates (**Fig. S4D**). Increasing concentrations of CipA of up to 2 µg/ml did not influence the generation of the surface-bound C3bB proconvertase (**Fig. S4E**).

To further investigate if CipA inhibits the C3bBb convertase formed in the fluid phase (29), the C3bB proconvertase was assembled by activating C3b-bound FB with FD in the presence and absence of CipA. Western blot analyses were investigated to detect cleavage of C3b generated by the assembled C3 convertase after 2 and 10 min and increased C3 concentrations (100 nM and 200 nM) (**Fig. S4F-I**). Collectively, the data of these analyses revealed that CipA did not have a strong impact on the generation of C3b (**Fig. S4G and I**) or targeted binding of FB to C3b (**Fig. S4F and H**).

Interaction of CipA with the C5 convertases of the AP and CP

Having demonstrated binding of CipA to C5 (**Fig. 2D**), we investigated CipA-mediated impairment of the C5 convertases of the AP and CP by determining the generation of C5a employing ELISA. NHS was added to microtiter plates coated with either lipopolysaccharide (for the AP) or human IgM (for the CP) to induce the formation of the C5 convertases (30). Purified C5 preincubated in the absence or presence of CipA, variant CipA ΔE360-K369, and variant CipA E360P, respectively, were then added to the wells and the release of generated C5a in the fluid phase was detected. Generation of C5a was significantly impaired in the presence of the WT CipA, while variants CipA ΔE360-K369 and CipA E360P lacking complement-inhibitory activity did not impact cleavage of C5 (**Fig. 3**). These findings suggest that CipA facilitates complement inactivation at least at the level of C5b generation.

CipA terminates complement activation by interaction with FI

The pronounced inhibitory capacity of CipA on the AP and the binding analyses indicate that an additional, yet unnoticed, molecular mechanism exists. Since we analyzed binding of the central components involved in AP and CP/LP activation, additional ELISA was conducted to investigate binding of CipA to FI. Thereby a strong affinity of CipA to FI with a dissociation constant of 3.0 nM (± 0.28 nM) (**Fig. 4A and B**). By employing N- and C-terminal CipA variants, deletion of the C-terminal domain resulted in a completely abrogation of the FI interaction (**Fig. 4C**). Interestingly, deletion of single or double amino acids as well as substitutions of single or multiple amino acids did not influenced the interaction of CipA with FI (**Fig. 4D**). To ensure that all positions of potential relevance within the C-terminus had been considered, *in vitro* mutagenesis was conducted to replace amino acids at the remaining positions 360, 361, and 362, respectively, by alanine (**Fig. 4E**). Apparently, none of the newly generated CipA variants exhibited any change in FI binding compared to CipA. Interestingly, replacement of glutamic acid by proline but not by alanine at position 360 drastically abolished binding as observed for CipA Δ E360-K369 lacking the 10 terminal amino acids. This suggests that proline changed the orientation of the C-terminus in such a way that FI was unable to bind to CipA. CipA E360P significantly lost the capacity to inhibit activation of the AP, CP, and LP compared to CipA (**Fig. S5**), indicating that the C-terminus is relevant for FI binding and complement inactivation.

To further confirm the significance of the C-terminus in the interaction with complement, sequence and structural predictions were conducted (**Fig. 5**). SignalP5.0 (31) predicts a lipoprotein signal peptide (Sec/SPII) with a cleavage site between positions 17 and 18 (LMA-CQ) with a very high probability of 0.9991. The first 17 amino acids were therefore removed for structural predictions. AlphaFold2 (32) predicts a protein consisting of a short, unstructured N-terminal region, followed by three approximately equally sized domains with

very high confidence (**Fig. 5A and B**). The three domains were identified by CDD/SPARKLE as two META domains (pfam03724) and one C-terminal DUF4377 domain (pfam14302; DUF, domain of unknown function). A strongly conserved DUF4377 is also found in other pathogenic bacteria associated with respiratory disease, such as *A. nosocomialis* (HCU39178; 99% sequence identity), *Klebsiella pneumoniae* (SSW87676.1; 100%), or bacteria related to non-respiratory diseases, e.g. *Enterobacter asburiae* (WP_194305131.1; 100%). META domains were first described in metacyclic stages of *Leishmania* (33), where the meta 1 gene is thought to be associated with virulence. The META1 domain (green) consists of 8 antiparallel beta-sheets flanked by two alpha-helices. A short linker connects it to the second META2 domain (orange), which has a similar arrangement of 8 anti-parallel beta sheets, but only one alpha-helix. This is connected by another short linker to the DUF4377 domain (blue), which consists entirely of beta-sheets. Glutamic acid at position 360 is located in the middle of the C-terminal beta-sheet strand of the DUF4377 domain (**Fig. 5C**). The introduction of a proline in position 360 disrupts the beta-sheet and dramatically alters the orientation of the last 10 C-terminal amino acids (**Fig. 5D**). A disruption of the protein fold by substitution of E360 with a proline is also predicted by Missense 3D (34). The pronounced effects on the structure of the C-terminal end of CipA are best appreciated in a short movie (**Fig. S8**).

CipA lacks intrinsic proteolytic activity but forms a quadripartite complex to terminate complement activation

To get a closer view into the molecular mechanism of complement inhibition mediated by CipA, we sought to exclude an intrinsic proteolytic activity of CipA as previously described for Pra1 of *Candida albicans* or SplB and ClpA of *Staphylococcus aureus* (35-38). CipA did not

exhibit proteolytic activity on C3b and C4b when assayed under different experimental conditions (**Fig. 6A to D**). In addition, C3 was still unaffected while an additional band of app. 90 kDa appears when C4 was investigated (**Fig. S6**).

To further explore the nature of the complement inhibitory activity, CipA variants lacking FI-binding capability were assayed with or without FI. Characteristic C3b and C4b cleavage products (41' and 43' fragments for C3b and 45 kDa fragment for C4b) could only be detected when FI bound to the immobilized WT CipA protein (**Fig. 6E and F**). By contrast, no degradation of C3b and C4b was observed in the absence of FI or when CipA variants lacking FI binding capability were investigated suggesting that cleavage occurs upon formation of a quadripartite complex consisting of CipA-FI-FH-C3b and CipA-FI-C4BP-C4b.

Recruitment of serum-derived FI facilitates complement resistance of *A. baumannii*

To investigate the impact of FI on complement resistance of *A. baumannii*, the $\Delta cipA$ strain was complemented by either the WT *cipA* gene (*Ab $\Delta cipA::cipA$*), a *cipA* gene with a deletion of 30 nucleotides at the C-terminus or a *cipA* gene with modifications at position 1078 (GAG → CCG; aa position 360: E → P) to produce variant CipA E360P using marker-less mutagenesis (22). Employing western blotting, *A. baumannii* 19606 WT as well as the complemented strains *Ab $\Delta cipA::cipA$* and *Ab $\Delta cipA::cipA$ E360P* produced the respective CipA protein (**Fig. 7A**). As expected, no signal could be detected for *Ab $\Delta cipA$* . In addition, a strong degradation pattern was observed for *Ab $\Delta cipA::cipA$ Δ E360-K369* suggesting that deletion of the C-terminus results in an enhanced susceptibility of CipA to proteolysis (**Fig. S7**).

Recruitment of serum-derived FI by *A. baumannii* was subsequently analyzed by incubating the three complemented strains with EDTA-NHS, and thereby surface-bound FI was detected

by Western blotting (**Fig. 7B**). *A. baumannii* 19606 and *Ab ΔcipA::cipA* bound FI from human serum, whereas no binding could be observed for *Ab ΔcipA* and *Ab ΔcipA::cipA* E360P, suggesting that they are unable to bind FI.

Having demonstrated binding of FI by native *A. baumannii* cells, we sought to investigate serum susceptibility to explore whether interaction with FI contribute to complement resistance of this pathogen. Strains *Ab ΔcipA::cipA*, *Ab ΔcipA*, and *Ab ΔcipA::cipA* E360P were incubated with increasing NHS concentrations and survival was determined (**Fig. 7C**). Compared to the CipA WT producing strain *Ab ΔcipA::cipA*, strains lacking FI binding capability displayed an increased susceptibility to complement-mediated killing, in particular strain *Ab ΔcipA::cipA* E360P (**Fig. 7D**). Taken together, these data indicate that (i) CipA is the sole FI-binding protein of *A. baumannii*, (ii) recruitment of FI to the surface of *A. baumannii* occurs in the presence of all serum proteins, and (iii) CipA plays an important part in complement resistance of the pathogen.

Discussion

Acinetobacter baumannii developed a number of versatile strategies to cope with the human immune system and thus, avoid recognition and eradication by complement as the first line of defense. Although numerous virulence factors and complement-affecting proteins have recently been described (15-23), the knowledge of the molecular mechanisms by which *A. baumannii* combat the effector function of complement is still in its infancy. Previously, we showed that CipA is able to inhibit complement activation by cleavage of the central component C3b following acquisition and activation of plasminogen (22). In this study, we expand our analyses and identify CipA as a multi-functional molecule of *A. baumannii* that interacts with diverse complement components including C3, C3b, C4b, C5,

FB, and, in particular FI. CipA is capable of inhibiting all three activation pathways at the level of C3 and C5. Moreover, our analyses employing numerous CipA variants identified the C-terminus as the most relevant structural element involved in complement inhibition (**Fig. 1 and S1**). CipA was also able to significantly inhibit the LP besides its property to inactivate the AP and CP (**Fig. S3**) indicating that inhibition occurs at the central hub of complement activation. Breakdown of the cascade by blocking the C3 convertases has also been reported for several immune evasion molecules secreted by *S. aureus* such as staphylococcal complement inhibitor (SCIN), extracellular fibrinogen-binding protein Efb, extracellular complement-binding protein Ecb, and the surface immunoglobulin-binding protein Sbi (27, 39-43). In contrast to the anti-complement activity of the staphylococcal immune evasion proteins, CipA does not inhibit the generation of the C3 convertases by binding to C3b and/or C3Bb or by formation of a tripartite complex consisting of CipA-C3b-FH (30, 40). Furthermore, Ecb is able to block C5 convertase activity by binding to C3b although C5 still binds to the formed C3 convertases (30). Here we showed that CipA binds to C3b and C5 (**Fig. 2B and 2D**) and impairs C5a generation (**Fig. 3**). Unlike Ecb, suppression of the enzymatic activity of the C5 convertases appears to follow a different mechanism of action as discussed below. CipA possess a strong inhibitory activity on the AP in comparison to Efb and Efb-C with a calculated IC_{50} of 14.5 nM, which is in the same range as reported for the staphylococcal proteins (**Fig. S1C and D**). Hence, the strong inactivation capacity makes CipA an attractive candidate in anti-inflammatory therapy. Future studies with appropriate infection models are necessary to prove whether this protein will serve as a suitable target for drug development.

So far, binding of serum FI has been described for *Prevotella intermedia* (44) and *S. aureus* (37, 38, 45, 46) whereby clumping factor A (ClfA) was identified as a cofactor for FI-mediated

degradation of C3b (37, 38). Contrary to what we observed for the CipA-FI interaction, binding of FI to ClfA enhance FI-mediated cleavage of C3b into iC3b in the absence of complement regulator FH (**Fig. 5**). In addition, CipA did not display intrinsic proteolytic activities on C3/C3b and C4b as demonstrated for other microbial proteins such as Pra1 of *Candida albicans* (35), SplB and aureolysin of *S. aureus* (36, 47), and NalP of *Neisseria meningitidis* (48). These findings indicate that the molecular mechanism by which CipA promotes degradation of C3/C3b as well as C4b in the presence of FI is unknown.

Our structural predictions obtained with AlphaFold2 are particularly beneficial for interpreting the results obtained with the various CipA variants. Inhibition of the alternative and classical pathways do not appear to involve the META1 domain, as its complete removal does not show any effect (**Fig. 1B and C**). In contrast, removal of the META2 and DUF4377 domains or the DUF4377 domain alone results in complete ablation of CipA's ability to inhibit the alternative pathway (**Fig. 1B**) and a partial reduction of the classical pathway inactivation capability (**Fig. 1C**). According to the AlphaFold2 structural prediction, the replacement of glutamic acid at position 360 with a proline results in a pronounced structural change in the C-terminal region of the DUF4377 domain, with complete loss of hydrogen bond pairing with the neighboring beta sheet. This alteration appears to have a strong impact on the ability of CipA to interact with FI (**Fig. 4E**) but did not affect interaction with C5 and FB (**Fig. S9**). Since substitutions with alanine at positions 360, 361 and 360, as well as deletions of single or multiple amino acids (**Fig. 4D**) had no effect on FI binding, the residues 360-369 are most likely not involved in direct FI binding. The dramatic rearrangement of the C-terminal portion in the E360P variant may instead disrupt other interactions between the DUF4377 domain and FI. The presence of a negative charge in position 360 also does not appear to play a role in the interaction with FI, as its substitution

with a neutral alanine had no effect on binding (**Fig. 4E**). Of note, the structural rearrangement of the C-terminal beta sheet dramatically results in destabilization of this domain due to loss of several hydrogen bonds and thereby hamper FI accumulation (**Fig. 5**). Our data indicate that CipA assists FI in assembling of a quadripartite complex consisting of either CipA·FI·C3b·FH or CipA·FI·C3b·C4BP to mediated cleavage of C3b and C4b (**Fig. 8**). To our knowledge, this is the first description of a bacterial molecule involved in the formation of a proposed high-ordered complex by initial binding of FI and subsequent recruitment of C3b/C4b and their respective complement regulators to promote complement inactivation (**Fig. 6 and 8**). The C-terminal domain seems to stabilize the binding of free FI in the CipA·FI complex as a starting point for the subordinate enzymatic active assembly. In addition, the relevance of FI acquisition for complement resistance of *A. baumannii* was confirmed by the generation of CipA deficient strains producing either wild-type CipA or a CipA protein lacking FI-binding capability. The higher susceptibility of the FI-negative complemented strain (**Fig. 7**) strongly indicates that recruitment of FI enables *A. baumannii* to resist complement-mediated killing under more physiological conditions. These data provide novel insights into the underlying mechanisms of immune evasion of *A. baumannii*.

With the worldwide emergence of CRAB and the lack of appropriate antimicrobials on the horizon, novel therapeutic considerations including preventive measurements are mandatory. Passive and active immunizations with inactivated *A. baumannii* cells, cell fractions or outer membrane vesicles were able to protect mice from infection with multiple *A. baumannii* strains (49, 50). Formulations containing individual proteins as potential vaccines such OmpA, trimeric autotransporter Ata, serine protease PKF, 3-O-deacylase PagL, biofilm-associated protein Bap or poly-N-acetyl- β -(1-6)-glucosamine (PNAG) also provide protection of mice (51-56). More recently, first vaccination trials employing a vaccine

containing CipA and the penicillin-binding protein PBP7/8 revealed that a combination of both proteins protects mice against infection with *A. baumannii* 19606 and induce strong cytokine responses towards IL-17 and IFN- γ (57). Due to its strong complement inactivating capacity, CipA is a promising candidate for the development of a suitable vaccine to prevent and treat serious infections caused by *A. baumannii*.

In conclusion, here we show that CipA (i) is a potent inhibitor of all three complement pathways (ii) acts as a key ligand for several complement components, and (iii) mediates formation of a quadripartite complex for FI-mediated cleavage of C3b and C4b in the presence of FH and C4BP. Acquisition of serum-derived FI appears to be an important mechanism of *A. baumannii* to evade complement-mediated bacteriolysis. The multifactorial and strong anti-complement activity of CipA raises the possibility to target this molecule as a promising therapeutic drug for the treatment of *A. baumannii*.

Materials and Methods

Bacterial strains and culture conditions

A. baumannii strain ATCC 19606^T (58), *A. baumannii* 19606 $\Delta cipA$ (22), *A. baumannii* $\Delta cipA::cipA$, *A. baumannii* $\Delta cipA::cipA$ $\Delta E360$ -K369, and *A. baumannii* $\Delta cipA::cipA$ E360P were grown at 37 °C in lysogeny broth (LB) or on LB agar plates. *Staphylococcus aureus* USA300, *Escherichia coli* JM109, BL21 Star™ (DE3), and NEB 5-alpha, respectively, were grown at 37 °C in yeast tryptone broth or on LB agar plates.

Proteins and antibodies

Purified complement proteins (C3, C3b, C4b, C5, FB, FD, FI, FH, C4BP) and the polyclonal anti-C5 antiserum were obtained from Complement Technology, Tyler, Texas, USA. Polyclonal antisera raised against complement C3, C4, and FH were from Merck (Darmstadt, Germany) and polyclonal antisera against FB and FI as well as the neoepitope-specific monoclonal antibody against C5b-9 were from Quidel, San Diego, USA. The monoclonal anti-FD antibody was from BioPorto Diagnostics A/S, Hellerup, Denmark. Anti-hexahistidine antibodies were from GE Healthcare, Chicago, Illinois, USA and Merck, respectively. Horseradish peroxidase (HRP)-conjugated immunoglobulins were obtained from Agilent Technologies Denmark, Glostrup, Denmark. The monoclonal anti-CipA antibody was described previously (22).

Generation and purification of recombinant proteins

The hexahistidine-tagged CipA protein lacking the N-terminal signal sequence and encompassing amino acid residues 19-369 (CipA Δ Q19-Q144), C-terminally truncated CipA variants CipA Δ L154-K369, CipA Δ Q291-K369, and CipA Δ A352-K369, respectively, as well as variant CipA K365A-K369A were described previously (22). To introduce single, double or multiple amino acid substitutions or deletions into the C-terminal region of CipA, site-directed mutagenesis was conducted as described (59). Briefly, PCR was carried out for 18 cycles (95°C for 1 min, 55 °C for 1 min and 72 °C for 7 min) using 50 ng/ μ l pQE-CipA, 125 ng each of the oligonucleotides (S1 Table), and 4 U PCRBIO HiFi polymerase (PCR Biosystems). Following incubation with 10 U *DpnI* (New England Biolabs) to eliminate the remaining vector DNA, reactions were used to transform *E. coli* cells. Plasmid DNA obtained from selected clones was isolated and mutations at the desired positions were confirmed by DNA sequence analysis of both strands. Production of His-tagged proteins in either *E. coli* JM109

or BL21 Star™ (DE3) and subsequent purification by affinity chromatography using Ni-NTA agarose were performed as previously described (60). The purity of recombinant proteins was analyzed by 10% Tris/Tricine SDS-PAGE and silver staining techniques and the protein concentrations were determined by employing the Pierce™ BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA).

To generate a His-tagged Efb protein as an additional control displaying complement inhibitory activity on the C3 convertase (27, 61), the Efb-encoding gene of *S. aureus* USA300 was amplified by PCR using primers Efb_FP Bam and Efb_RP Sal (S1 Table). The amplified DNA fragment was then cloned into pQE-30 Xa (Qiagen, Hilden, Germany) yielding plasmid pQE-Efb. To generate a C-terminal fragment of Efb, plasmid pQE-Efb was used as template for PCR using primers pQE-RP in combination with Efb-C_FP_Bam. The resulting PCR product was cloned into pQE-30 Xa and the generated pQE-Efb-C plasmid was sequenced for verification.

Enzyme-linked immunosorbent assay (ELISA)

To detect binding of complement components, Nunc MaxiSorp 96-well microtiter plates (Thermo Fisher Scientific) were coated with 100 µl of purified bacterial proteins (5 µg/ml) or BSA (5 µg/ml) in PBS at 4 °C overnight as described (62). Between every incubation step, wells were washed three times with PBS containing 0.05% (v/v) Tween 20 (PBS-T). After blocking with Blocking Buffer III BSA (AppliChem, Darmstadt, Germany) or with PBS containing 0.2% gelatine (w/v) (AppliChem), complement components (100 ng/ml) in PBS were added to the wells. Binding of complement components were then assessed by utilizing specific primary antibodies (dilution 1:1,000). Following incubation for 1 h at RT, HRP-conjugated anti-goat or anti-mouse IgG (dilution 1:1,000) were added and protein

complexes were visualized using *o*-phenylenediamine (Merck). The absorbance was then measured at 490 nm employing PowerWave HT (Bio-Tek Instruments, Winooski, VT, USA). To determine dose-dependency and to calculate the dissociation constant, CipA was immobilized (5 µg/ml) and incubated with increasing amounts (0 to 50 nM) of C3b, C5, and FI, respectively. The antigen-antibody complexes were detected by using the appropriate antibodies as described above.

Complement inactivation assays

To assess the inhibitory capacity of CipA and CipA variants on the classical (CP) and alternative (AP) pathway, an ELISA-based complement inactivation assay was conducted as described (63). Briefly, microtiter plates coated with either human IgM (30 ng/ml) (Merck, No I8260) for the CP, lipopolysaccharide from *Salmonella enteridis* (100 ng/ml) (Hycult Biotech Uden, The Netherlands) for the AP or mannan (1 µg/ml) (Merck) for the LP were incubated ON at 4 °C. After washing with TBS containing 0.05% (v/v) Triton X-100 (TBS-T), the plates were blocked with PBS-T containing 1% BSA for 1 h at RT. Between every incubation step, wells were washed three times with TBS-T. NHS (15% for the AP, 1% for the CP and 2% for the LP) was pre-incubated for 15 min at 37 °C with purified proteins (500 nM for AP and 2.5 µM for the CP and LP, respectively) and reactions were added to initiate complement activation. Formation of the MAC was detected by using a monoclonal anti-C5b-9 antibody (1:500) (Quidel, San Diego, CA, USA) followed by HRP-conjugated anti-mouse IgG (1:1,000). The reaction complexes were developed as described above.

Generation of a solid-phase C3bB proconvertase

An ELISA-based approach was conducted to generate a Ni^{2+} -dependent C3bB proconvertase as described (28, 29). Microtiter plates were coated with 3 $\mu\text{g}/\text{ml}$ C3b in PBS overnight at 4 °C, blocked with TBS-T containing 1% BSA, and incubated for 1 h at 37 °C with 800 ng/ml FB dissolved in phosphate buffer supplemented with 2 mM NiCl_2 , 4% BSA and 0.1% Tween 20. For initial experiments increasing concentrations of FB (0, 10, 20, 40, 80, 100, 200, 400, and 800 ng/ml) was employed. Binding of FB to C3b was detected using a polyclonal anti-FB antibody followed by a HRP-conjugated anti-goat IgG (1:1000). The reactions were developed as described above.

Interaction of CipA with the C3bB proconvertase

The inhibitory capacity of CipA on the formation of the C3bB proconvertase was determined by using ELISA. Microtiter plates were coated overnight at 4 °C with CipA (5 ng/ μl) in PBS and C3b (3 ng/ μl) for control purposes respectively. After washing, wells were blocked with TBS-T containing 1% BSA and incubated for 1 h at 37 °C. After washing, C3b (3 ng/ μl) dissolved in phosphate buffer supplemented with 2 mM NiCl_2 , 4% BSA and 0.1% Tween 20 was added and incubated for 1 h at 37 °C. Following washing, FB (8 ng/ μl) resuspended in phosphate buffer supplemented with 2 mM NiCl_2 , 4% BSA and 0.1% Tween 20 were added and microtiter plates were incubated for 2 h at 37 °C. Binding of FB was detected using a polyclonal anti-FB antibody followed by a HRP-conjugated anti-goat IgG.

Binding of CipA to the fluid-phase C3 convertase of the alternative pathway

To assess the ability of CipA to inhibit the assembly of the C3 convertase of the alternative pathway, the C3Bb complex was initially formed in solution as described (29). Briefly, C3b (200 nM), FB (100 nM), and FD (50 nM) were incubated in HBS-N (10 mM HEPES, 150 mM

NaCl, 2 mM MgCl₂, pH 7.4) for 2 min at RT. The reaction was then terminated by adding 5 mM EDTA and purified C3 was added at two different concentrations (100 nM and 200 nM) in the absence or presence of 1 μM CipA. Following incubation of 20 min at RT, Tris/Tricine incubation buffer was added and the proteins were separated by 10% Tris/Tricine SDS-PAGE and transferred to nitrocellulose. C3, FB, and cleavage products thereof were then detected by using anti-C3 and and FB polyclonal antibodies.

The CipA-mediated inhibition on the formation of the fluid-phase C3b proconvertase was investigated by preincubation of CipA (1 μM) with C3b (200 nM) for 15 min at RT. After adding FB (100 nM) and FD (50 nM) the reactions were initially incubated for 2 min at RT, and the reaction mixtures were then terminated with 5 mM EDTA. In addition, C3b (200 nM), FB (100 nM), and FD (50 nM) were incubated in the presence of CipA (1 μM) for 0, 2, and 10 min at RT. The reactions were then terminated by adding Tris/Tricine incubation buffer following separation through 10% Tris/Tricine SDS-PAGE. Detection of C3 and FB was performed by Western blotting as described above.

Inhibition of the C5 convertases activity by CipA

The impact of CipA on the enzymatic activity of the C5 convertases was assessed by ELISA. Microtiter plates were coated overnight at 4 °C with either human IgM (30 ng/ml) for the CP or LPS (100 ng/ml) for the AP. After washing three times with PBS-T, wells were blocked with PBS containing 4% BSA and 0,1% Tween 20. To generate the C5 convertases, human serum (1% for the CP and 15% for the AP) was added and incubated for 1 h at 37 °C as described (30). After washing, the wells were then incubated with NHS for 1 h at 37 °C. Purified C5 (100 ng) and CipA (460 ng) as well as variants CipA ΔE360-K369 and CipA ΔE360P were pre-incubated in PBS for 30 min at 37 °C and then added to the wells for an additional incubation

of 1 h at 37 °C. For control purposes, preincubated C5 was also added to the wells in the absence of CipA. Cleavage of C5 and detection of released C5a by the formed C5 convertases was detected using the MicroVue C5a EIA (Quidel) and the absorbance was then measured at 490 nm.

Determination of the intrinsic proteolytic activity of CipA

To determine intrinsic proteolytic activity of CipA in FI-mediated inactivation of C3b, microtiter plates were coated with either CipA (5 ng/μl or 30 ng/μl) or BSA (5 ng/μl) overnight at 4 °C according to Hair et al. (38). After washing with PBS containing 0.05% (v/v) Tween 20 (PBS-T), wells were blocked with PBS containing 0.2% gelatine (w/v). Thereafter, reaction mixtures with C3b (1 μg) and FI (500 ng) or in which FI was omitted were added and the microtiter plates were incubated for different times points at RT and 37 °C, respectively. The reactions were then terminated by adding Tris/Tricine incubation buffer and mixtures removed were subjected to SDS-PAGE. After transfer to nitrocellulose membranes, C3b degradation products were visualized by a polyclonal anti-C3 antibody. As a positive control, C3b (600 ng) were incubated with FI (300 ng) and FH (10 ng) for 1 h at 37 °C and the reaction was then subjected to SDS-PAGE and Western blotting.

In addition, microtiter plates coated with CipA, CipA ΔE360-K369 or CipA E360P (5 ng/μl each) were incubated for 1 h at RT in the absence or presence of FI (5 ng/μl). After washing, reaction mixtures containing C3b and FH or C4b and C4BP were added to the microtiter plates. After incubation for 1 h at 37 °C reaction mixtures were transferred to tubes and reactions were terminated by adding Tris/Tricine incubation buffer. The samples were subjected to 10% Tris/Tricine SDS-PAGE following Western blotting. Control reactions containing C3b, FI, and FH or C4b, FI, and C4BP were incubated for 1 h at 37

°C and for 2 h at 37 °C, respectively. The reaction mixtures were terminated by adding Tris/Tricine incubation buffer and subjected to SDS-PAGE. After transfer to nitrocellulose membranes, C3b and C4b degradation products were visualized by using a polyclonal anti-C3 antibody (1:1,000) and a mixture of a polyclonal anti-C4 (1:1,000) and a monoclonal anti-C4d antibody (1:100).

Generation of *A. baumannii* strains producing diverse CipA variants

For complementation of *A. baumannii* 19606 $\Delta cipA$, different vectors were generated harboring the (i) WT *cipA* gene, (ii) *cipA* gene with a stop codon for production of a CipA protein lacking 10 amino acids at the C-terminus (CipA $\Delta E360-K369$), (iii) *cipA* gene with a substitution at aa position 360 (CipA E360P). Initially, the CipA encoding gene containing up- and downstream regions was amplified from *A. baumannii* 19606^T by using primers CipA up fwd PstI and CipA down rev NotI. Following digestion with PstI and NotI, the resulting DNA fragment was cloned into the PstI/NotI sites of pCR 2.1 TOPO vector generating pCR_nc5_CipA_nc3. This vector serves as template for a subsequent PCR amplification with primers CipA V359 FP and CipA V359 RP to introduce two stop codons at aa position 359 and 360 in *cipA*. The DNA fragment was then digested with the respective restriction endonucleases and also cloned into pCR 2.1 TOPO vector resulting in pCR_nc5_CipA-359_nc3. Afterwards, the inserted DNA fragments were re-amplified, digested, and re-cloned into pBISK_sacBkanR (64) resulting in vectors pBISK_nc5_CipA_nc3 and pBISK_nc5_CipA-359_nc3, respectively. In addition, pBISK_nc5_CipA_nc3 was also used for *in vitro* mutagenesis to introduce a single substitution at position 360 (E to P) applying primers CipA E360P_II FP and CipA E360P_II RP. The vectors generated were then used to transform *A. baumannii* 19606 $\Delta cipA$ by a markerless mutagenesis approach as previously

described (64). Briefly, kanamycin-resistant complemented cells were counter-selected with 10% sucrose to allow integration of the inserts into the genome of *A. baumannii* 19606 Δ CipA by homologous recombination. Selected clones were subjected to PCR analyses using primers CipA seq Fwd and CipA seq Rev to ensure that the fragments were correctly integrated and no additional mutations have been introduced in the CipA encoding gene and the 5' and 3' flanking regions during the cloning procedure. Sequence verification of *cipA* mutants was done by whole genome sequencing (WGS) as previously described (65). Briefly, DNA was extracted from isolates and WGS was carried out using the Illumina® MiSeq platform generating 250bp paired-end reads with coverage of >50. Assembly and scaffolding after quality trimming of the reads was conducted using SPAdes v3.15.0. Sequences were mapped against the reference sequence (CP045110.1) and *cipA* was analyzed using Geneious 11.1.52.

Recruitment of serum-derived FI by native *A. baumannii* cells

Binding of FI to *A. baumannii* 19606 WT, Δ *cipA* (22), Δ *cipA::cipA*, Δ *cipA::cipA* Δ E360-K369 and Δ *cipA::cipA* E360P was assessed by a serum adsorption assay as described previously (66). Briefly, bacterial cells grown to an OD₆₀₀ of 0.5 were sedimented and resuspended in PBS⁺⁺. Cells (1×10^{10}) were incubated in 750 μ l NHS-EDTA for 1 h at 37 °C. After washing, proteins bound to the bacterial surface were eluted by using 0.1 M glycine-HCl, pH 2.0. After adding 1 M Tris-HCl (pH 9.0), the cell debris were sedimented and the supernatant were analyzed by SDS-PAGE and Western blotting by using a polyclonal anti-FI antibody as described above.

Serum susceptibility testing of *A. baumannii* strains

Serum susceptibility of *A. baumannii* $\Delta cipA$, $\Delta cipA::cipA$, and *A. baumannii* $\Delta cipA::cipA$ E360P was assessed by suspending 2.5×10^7 cells in PBS-diluted NHS (40% to 70%) following incubation at 37 °C for 2 h. Bacteria were serially diluted in PBS, plated onto LB agar plates and colony-forming units (CFU) were determined on the next day. The CFU counts were related to controls which were incubated with LB medium instead of NHS. The survival of bacteria in LB medium was set at 100% to compare the serum susceptibility of the complemented strains.

Structure prediction analyses

The protein sequence of CipA (NCBI reference sequence WP 000696035.1) was used for structural prediction. After removal of the N-terminal 17 amino acid signal sequence, the mature protein sequence was submitted on the AlphaFold 2 advanced interface (67) with the default settings using the optional “Refine structures with Amber-Relax” option. Results were exported to UCSF ChimeraX 1.2.5. (68), using the Matchmaker function for the overlay of the DUF4377 domain in the WT CipA and variant CipA E360.

Statistical analyses

The data collected represent means from at least three independent experiments, and error bars indicate SD. For statistical analyses, one-way ANOVA with Bonferroni’s multiple comparison post-hoc test (95% confidence interval) or a two-tailed, unpaired t-test were conducted by applying GraphPad Prism version 7.

Ethics statement

The study and respective documents were approved by the ethics committee at the University Hospital of Frankfurt (control number 492/13). All healthy blood donors provided written informed consent in accordance with the Declaration of Helsinki.

Acknowledgments

We thank Arno Koenigs for critical reading of the manuscript.

Funding

FHF is fully funded by the LOEWE Centre DRUID within the Hessian Excellence Initiative. SG is supported by the German Research Foundation (DFG research unit 2251 *Acinetobacter baumannii*, project P3).

References

1. M. Kempf, J. M. Rolain, Emergence of resistance to carbapenems in *Acinetobacter baumannii* in Europe: clinical impact and therapeutic options. *Int J Antimicrob Agents* **39**, 105-114 (2012).
2. L. Dijkshoorn, A. Nemec, H. Seifert, An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* **5**, 939-951 (2007).
3. F. Löttsch *et al.*, Epidemiological situation, laboratory capacity and preparedness for carbapenem-resistant *Acinetobacter baumannii* in Europe, 2019. *Euro Surveill* **25** (2020).
4. S. Göttig *et al.*, Detection of pan drug-resistant *Acinetobacter baumannii* in Germany. *J Antimicrob Chemother* **69**, 2578-2579 (2014).
5. R. Valencia *et al.*, Nosocomial outbreak of infection with pan-drug-resistant *Acinetobacter baumannii* in a tertiary care university hospital. *Infect Control Hosp Epidemiol* **30**, 257-263 (2009).
6. P. G. Higgins, C. Dammhayn, M. Hackel, H. Seifert, Global spread of carbapenem-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother* **65**, 233-238 (2010).
7. E. Tacconelli *et al.*, Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis* **18**, 318-327 (2018).
8. C. M. Harding, S. W. Hennon, M. F. Feldman, Uncovering the mechanisms of *Acinetobacter baumannii* virulence. *Nat Rev Microbiol* **16**, 91-102 (2018).
9. M. J. McConnell, L. Actis, J. Pachon, *Acinetobacter baumannii*: human infections, factors contributing to pathogenesis and animal models. *FEMS microbiology reviews* **37**, 130-155 (2013).
10. D. Ricklin, G. Hajishengallis, K. Yang, J. D. Lambris, Complement: a key system for immune surveillance and homeostasis. *Nat Immunol* **11**, 785-797 (2010).

- 607 11. D. Ricklin, E. S. Reis, J. D. Lambris, Complement in disease: a defence system turning
608 offensive. *Nat Rev Nephrol* **12**, 383-401 (2016).
- 609 12. N. S. Merle, S. E. Church, V. Fremeaux-Bacchi, L. T. Roumenina, Complement System Part I -
610 Molecular Mechanisms of Activation and Regulation. *Front Immunol* **6**, 262 (2015).
- 611 13. P. F. Zipfel, C. Skerka, Complement regulators and inhibitory proteins. *Nat Rev Immunol* **9**,
612 729-740 (2009).
- 613 14. S. A. Tsiftoglou *et al.*, The catalytically active serine protease domain of human complement
614 factor I. *Biochemistry* **44**, 6239-6249 (2005).
- 615 15. S. W. Kim *et al.*, Serum resistance of *Acinetobacter baumannii* through the binding of factor H
616 to outer membrane proteins. *FEMS Microbiol Lett* **301**, 224-231 (2009).
- 617 16. T. A. Russo *et al.*, Penicillin-binding protein 7/8 contributes to the survival of *Acinetobacter*
618 *baumannii* in vitro and in vivo. *J Infect Dis* **199**, 513-521 (2009).
- 619 17. L. B. King, M. K. Pangburn, L. S. McDaniel, Serine protease PKF of *Acinetobacter baumannii*
620 results in serum resistance and suppression of biofilm formation. *J Infect Dis* **207**, 1128-1134
621 (2013).
- 622 18. A. Koenigs, P. F. Zipfel, P. Kraiczy, Translation elongation factor Tuf of *Acinetobacter*
623 *baumannii* is a plasminogen-binding protein. *PLoS ONE* **10**, e0134418 (2015).
- 624 19. A. C. Jacobs *et al.*, Inactivation of phospholipase D diminishes *Acinetobacter baumannii*
625 pathogenesis. *Infect Immun* **78**, 1952-1962 (2010).
- 626 20. D. Liu *et al.*, Characterization of surface antigen protein 1 (SurA1) from *Acinetobacter*
627 *baumannii* and its role in virulence and fitness. *Vet Microbiol* **186**, 126-138 (2016).
- 628 21. M. Weidensdorfer *et al.*, The *Acinetobacter* trimeric autotransporter adhesin Ata controls key
629 virulence traits of *Acinetobacter baumannii*. *Virulence* **10**, 68-81 (2019).
- 630 22. A. Koenigs *et al.*, CipA of *Acinetobacter baumannii* is a novel plasminogen binding and
631 complement inhibitory protein. *Journal of Infectious Diseases* **213**, 1388-1399 (2016).
- 632 23. F. C. Morris, C. Dexter, X. Kostoulas, M. I. Uddin, A. Y. Peleg, The Mechanisms of Disease
633 Caused by *Acinetobacter baumannii*. *Front Microbiol* **10**, 1601 (2019).
- 634 24. T. Hallström *et al.*, CspA from *Borrelia burgdorferi* inhibits the terminal complement
635 pathway. *MBio* **4** (2013).
- 636 25. T. Hallström, E. Trajkovska, A. Forsgren, K. Riesbeck, *Haemophilus influenzae* surface fibrils
637 contribute to serum resistance by interacting with vitronectin. *J Immunol* **177**, 430-436
638 (2006).
- 639 26. C. Hammerschmidt *et al.*, BGA66 and BGA71 facilitate complement resistance of *Borrelia*
640 *bavariensis* by inhibiting assembly of the membrane attack complex. *Molecular Microbiology*
641 **99**, 407-424 (2016).
- 642 27. I. Jongerius *et al.*, Staphylococcal complement evasion by various convertase-blocking
643 molecules. *Journal of Experimental Medicine* **204**, 2461-2471 (2007).
- 644 28. D. E. Hourcade, L. Mitchell, L. A. Kuttner-Kondo, J. P. Atkinson, M. E. Medof, Decay-
645 accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the
646 complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb. *J Biol Chem* **277**,
647 1107-1112 (2002).
- 648 29. A. F. Mendes-Sousa *et al.*, The sand fly salivary protein lufaxin inhibits the early steps of the
649 alternative pathway of complement by direct binding to the proconvertase C3b-B. *Front*
650 *Immunol* **8**, 1065 (2017).
- 651 30. I. Jongerius, B. L. Garcia, B. V. Geisbrecht, J. A. G. van Strijp, S. H. M. Rooijackers, Convertase
652 inhibitory properties of staphylococcal extracellular complement-binding protein. *J Biol Chem*
653 **285**, 14973-14979 (2010).
- 654 31. J. J. Almagro Armenteros *et al.*, SignalP 5.0 improves signal peptide predictions using deep
655 neural networks. *Nat Biotechnol* **37**, 420-423 (2019).
- 656 32. J. Jumper *et al.*, Highly accurate protein structure prediction with AlphaFold. *Nature* **596**,
657 583-589 (2021).

- 658 33. S. R. Uliana, N. Goyal, E. Freymuller, D. F. Smith, *Leishmania*: overexpression and
659 comparative structural analysis of the stage-regulated meta 1 gene. *Exp Parasitol* **92**, 183-
660 191 (1999).
- 661 34. S. Ittisoponpisan *et al.*, Can predicted protein 3D structures provide reliable insights into
662 whether missense variants are disease associated? *J Mol Biol* **431**, 2197-2212 (2019).
- 663 35. S. Luo *et al.*, The secreted *Candida albicans* protein Pra1 disrupts host defense by broadly
664 targeting and blocking complement C3 and C3 activation fragments. *Mol Immunol* **93**, 266-
665 277 (2018).
- 666 36. P. Dasari *et al.*, The protease SplB of *Staphylococcus aureus* targets host complement
667 components and inhibits complement-mediated bacterial opsonophagocytosis. *J Bacteriol*
668 10.1128/JB.00184-21, JB0018421 (2021).
- 669 37. P. S. Hair *et al.*, Clumping factor A interaction with complement factor I increases C3b
670 cleavage on the bacterial surface of *Staphylococcus aureus* and decreases complement-
671 mediated phagocytosis. *Infect Immun* **78**, 1717-1727 (2010).
- 672 38. P. S. Hair, M. D. Ward, O. J. Semmes, T. J. Foster, K. M. Cunnion, *Staphylococcus aureus*
673 clumping factor A binds to complement regulator factor I and increases factor I cleavage of
674 C3b. *J Infect Dis* **198**, 125-133 (2008).
- 675 39. S. H. Rooijackers *et al.*, Immune evasion by a staphylococcal complement inhibitor that acts
676 on C3 convertases. *Nat Immunol* **6**, 920-927 (2005).
- 677 40. K. Haupt *et al.*, The *Staphylococcus aureus* protein Sbi acts as a complement inhibitor and
678 forms a tripartite complex with host complement factor H and C3b. *PLoS Pathog* **4**, e1000250
679 (2008).
- 680 41. I. Jongerius *et al.*, *Staphylococcus aureus* virulence is enhanced by secreted factors that block
681 innate immune defenses. *J Innate Immun* **4**, 301-311 (2012).
- 682 42. S. H. Rooijackers *et al.*, Staphylococcal complement inhibitor: structure and active sites. *J*
683 *Immunol* **179**, 2989-2998 (2007).
- 684 43. D. Ricklin, Manipulating the mediator: modulation of the alternative complement pathway
685 C3 convertase in health, disease and therapy. *Immunobiology* **217**, 1057-1066 (2012).
- 686 44. S. Malm *et al.*, Acquisition of complement inhibitor serine protease factor I and its cofactors
687 C4b-binding protein and factor H by *Prevotella intermedia*. *PLoS One* **7**, e34852 (2012).
- 688 45. K. M. Cunnion, E. S. Buescher, P. S. Hair, Serum complement factor I decreases
689 *Staphylococcus aureus* phagocytosis. *J Lab Clin Med* **146**, 279-286 (2005).
- 690 46. K. M. Cunnion, P. S. Hair, E. S. Buescher, Cleavage of complement C3b to iC3b on the surface
691 of *Staphylococcus aureus* is mediated by serum complement factor I. *Infect Immun* **72**, 2858-
692 2863 (2004).
- 693 47. A. J. Laarman *et al.*, *Staphylococcus aureus* metalloprotease aureolysin cleaves complement
694 C3 to mediate immune evasion. *J Immunol* **186**, 6445-6453 (2011).
- 695 48. E. Del Tordello, I. Vacca, S. Ram, R. Rappuoli, D. Serruto, *Neisseria meningitidis* NaP cleaves
696 human complement C3, facilitating degradation of C3b and survival in human serum. *Proc*
697 *Natl Acad Sci U S A* **111**, 427-432 (2014).
- 698 49. M. J. McConnell *et al.*, Vaccination with outer membrane complexes elicits rapid protective
699 immunity to multidrug-resistant *Acinetobacter baumannii*. *Infect Immun* **79**, 518-526 (2011).
- 700 50. M. J. McConnell, C. Rumbo, G. Bou, J. Pachon, Outer membrane vesicles as an acellular
701 vaccine against *Acinetobacter baumannii*. *Vaccine* **29**, 5705-5710 (2011).
- 702 51. Y. Fattahian *et al.*, Protection against *Acinetobacter baumannii* infection via its functional
703 deprivation of biofilm associated protein (Bap). *Microb Pathog* **51**, 402-406 (2011).
- 704 52. G. Luo *et al.*, Active and passive immunization protects against lethal, extreme drug resistant-
705 *Acinetobacter baumannii* infection. *PLoS One* **7**, e29446 (2012).
- 706 53. L. V. Bentancor, J. M. O'Malley, C. Bozkurt-Guzel, G. B. Pier, T. Maira-Litran, Poly-N-acetyl-
707 beta-(1-6)-glucosamine is a target for protective immunity against *Acinetobacter baumannii*
708 infections. *Infect Immun* **80**, 651-656 (2012).

54. L. V. Bentancor *et al.*, Evaluation of the trimeric autotransporter Ata as a vaccine candidate against *Acinetobacter baumannii* infections. *Infect Immun* **80**, 3381-3388 (2012).
55. N. Bolourchi *et al.*, Immunogenic reactivity of recombinant PKF and AbOmpA proteins as serum resistance factors against sepsis of *Acinetobacter baumannii*. *Microb Pathog* **131**, 9-14 (2019).
56. F. Badmasti *et al.*, Immunological evaluation of OMV_(PagL)+Bap_(1-487aa) and AbOmpA_(8-346aa)+Bap_(1-487aa) as vaccine candidates against *Acinetobacter baumannii* sepsis infection. *Mol Immunol* **67**, 552-558 (2015).
57. F. Badmasti *et al.*, The combination of CipA and PBP-7/8 proteins contribute to the survival of C57BL/6 mice from sepsis of *Acinetobacter baumannii*. *Microb Pathog* **158**, 105063 (2021).
58. Y. Pfeifer *et al.*, Molecular characterization of blaNDM-1 in an *Acinetobacter baumannii* strain isolated in Germany in 2007. *J Antimicrob Chemother* **66**, 1998-2001 (2011).
59. P. Kraiczy *et al.*, Assessment of the regions within complement regulator-acquiring surface protein (CRASP)-2 of *Borrelia burgdorferi* required for interaction with host immune regulators FHL-1 and factor H. *International Journal of Medical Microbiology* **298**, 268-271 (2008).
60. A. Koenigs *et al.*, BBA70 of *Borrelia burgdorferi* is a novel plasminogen-binding protein. *Journal of Biological Chemistry* **288**, 25229-25243 (2013).
61. L. Y. Lee, X. Liang, M. Hook, E. L. Brown, Identification and characterization of the C3 binding domain of the *Staphylococcus aureus* extracellular fibrinogen-binding protein (Efb). *J Biol Chem* **279**, 50710-50716 (2004).
62. C. Hammerschmidt *et al.*, Versatile roles of CspA orthologs in complement inactivation of serum-resistant Lyme disease spirochetes. *Infection and Immunity* **82**, 380-392 (2014).
63. L. Walter *et al.*, Elucidating the immune evasion mechanisms of *Borrelia mayonii*, the causative agent of Lyme disease. *Front Immunol* **10**, 2722 (2019).
64. J. Stahl, H. Bergmann, S. Gottig, I. Ebersberger, B. Averhoff, *Acinetobacter baumannii* virulence is mediated by the concerted action of three phospholipases D. *PLoS One* **10**, e0138360 (2015).
65. M. Tietgen *et al.*, Identification of the novel class D beta-lactamase OXA-679 involved in carbapenem resistance in *Acinetobacter calcoaceticus*. *J Antimicrob Chemother* **74**, 1494-1502 (2019).
66. P. Kraiczy, C. Skerka, M. Kirschfink, V. Brade, Peter F. Zipfel, Immune evasion of *Borrelia burgdorferi* by acquisition of human complement regulators FHL-1/reconectin and Factor H. *Eur J Immunol* **31**, 1674-1684 (2001).
67. M. Mirdita *et al.*, ColabFold - Making protein folding accessible to all. *Research Square* 10.21203/rs.3.rs-1032816/v1 (2021).
68. E. F. Pettersen *et al.*, UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Sci* **30**, 70-82 (2021).

Figure legends

Fig 1. Assessment of the inhibitory capacity of CipA and CipA variants on activation of the AP and CP. Schematic representation of N- and C-terminal deletion CipA variants and structure predictions generating by using AlphaFold2.0 **(A)**. Deletions are as follows: CipA ΔQ19-Q144 removes the whole META1 domain (green), CipA ΔL154-K369 removes the META2 (orange) and DUF4377 (blue) domains, while the CipA ΔQ291-K369 deletion removes

most of the DUF4377 domain. Schematic representation of CipA variants carrying single and multiple deletions or substitutions (in red letters) **(D)**. WiELISA were performed to assess the inhibitory capacity of CipA deletion variants on the AP **(B and E)** and CP **(C and F)**. NHS pre-incubated with the purified CipA proteins or BSA (500 nM for AP and 2.5 μ M for the CP) were added to microtiter plates immobilized with LPS (AP) or IgM (CP). Formation of the MAC was detected by using a monoclonal anti-C5b-9 antibody. Data represent means and standard deviation of at least three different experiments, each conducted in triplicate. ****, $p \leq 0.0001$, n.s., no statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%).

Fig 2. Binding of CipA to different complement components of the AP and CP. Protein binding of C3 **(A)**, C3b **(B)**, C3c **(C)**, C5 **(D)**, C4b **(E)**, FB **(F)**, FD **(G)**, and FH **(H)**, respectively, to CipA to was measured by ELISA. CipA (5 ng/ μ l) was immobilized and incubated with 5 ng/ μ l purified complement components and BSA or gelatine were used as negative controls (ctrl). Bound complement components were detected using specific antisera (1:1,000). To assess statistical significance, two-tailed, unpaired Student's t-test was performed. Data represent means and/or standard deviation of at least three different experiments, each conducted in at least triplicate. **, $p \leq 0.05$; ****, $p \leq 0.0001$; n.s., no statistical significance.

Fig 3. Impact of CipA on the enzymatic activity of the C5 convertases. The influence of CipA on the C5 convertase was analyzed by measuring the generation of C5a. The C5 convertases (AP and CP) were constituted on microtiter plates coated with LPS or IgM by adding NHS. Thereafter, reaction mixtures of C5 preincubated with or without CipA variants were added. The generation and release of C5a in the supernatant was then detected by C5a ELISA. Data

represent means and standard deviation of at least three independent experiments, each conducted in duplicate. ***, $p \leq 0.0002$; ****, $p \leq 0.0001$, n.s., no statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%).

Fig 4. Interaction of CipA with FI. Protein binding of FI to CipA was measured by ELISA (**A** and **B**). CipA-coated wells (5 ng/ μ l) were incubated with 5 ng/ μ l purified FI and protein complexes were detected using an anti-FI antibody (1:1,000). To assess statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%) was performed. Data represent means and standard deviation of at least three different experiments, each conducted in at least triplicate. ****, $p \leq 0.0001$. Dose-dependent binding of FI to CipA (**B**). CipA (5 ng/ μ l) immobilized was incubated with increasing concentrations (0 to 25 nM) of purified FI and dissociation constant was approximated via non-linear regression, using a one-site, specific binding model. Data represent means and standard deviation of at least three different experiments, each conducted in triplicate. Detection of the FI-interacting region within CipA employing diverse CipA variants (**C** to **E**). Microtiter plates coated with CipA and CipA variants (5 ng/ μ l) were incubated with FI (10 ng/ μ l) and binding was detected by an anti-Fi antibody (1:1,000). BSA was used as negative control in all assays. Data represent means and standard deviation of at least three different experiments, each conducted in triplicate. **, $p \leq 0.05$, ****, $p \leq 0.0001$, n.s., no statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%).

Fig 5. Structural prediction of CipA obtained with AlphaFold2. The mature CipA₁₈₋₃₆₉ protein has a short, 11 amino acid-long unstructured N-terminus (**A**), followed by three approximately equally sized domains (**B**), recognized as META domain 1 (AA 46-107), META domain 2 (AA 151-253) and a C-terminal domain of unknown function, DUF4377 (AA 277-361). The DUF4377 domain is made up entirely of beta-sheets, the last of which contains the E360 residue in WT CipA (blue, E360 highlighted in yellow in **C**) which was mutagenized to proline in the E360P mutant (beige, P360 highlighted in red in **C**). Introduction of this amino acid disrupts the final beta-sheet strands and results in reorientation of the last 9 C-terminal amino acids (**D**), away from the DUF4377 domain, but without any overt effect on the other parts of the molecule.

Fig 6. CipA lacks intrinsic proteolytic activity on C3b and C4b and formation of a quadripartite complex to inactivate C3b and C4b. Intrinsic proteolytic activity of CipA in FI-mediated inactivation of C3b was assessed by Western blotting (**A** to **C**). CipA or BSA coated wells were incubated with C3b or with C3b and FI for 1 h (**A**) and 6 h (**B**) at RT or for 6 h at 37 °C (**C**). After termination, C3b degradation products were visualized by Western blotting employing a polyclonal anti-C3 antibody. Detection of CipA (**D**) in reaction mixtures shown in (**C**) by using an anti-CipA antibody (22). Formation of a quadripartite complex results in inactivation of C3b (**E**) and C4b (**F**). Microtiter plates coated with CipA, CipA Δ E360-K369 or CipA E360P (5 ng/ μ l) were incubated in the absence (-FI) or presence of FI (+FI). Thereafter, reaction mixtures containing C3b and FH or C4b and C4BP were added to the wells and were then subjected to SDS-PAGE and Western blotting. C3b and C4b degradation products were visualized by using an anti-C3 antibody and a mixture containing an anti-C4 and anti-C4d antibody. Control reactions containing C3b, FI, and FH as well as C4b, FI, and C4BP.

825

826 **Fig 7. Recruitment of serum-derived FI to CipA mediates escape of *A. baumannii* from**

827 **complement-mediated killing.** CipA production in different *A. baumannii* strains was verified

828 by Western blot analysis **(A)**. CipA was detected in *A. baumannii* cell lysates (10 µg each) by

829 using an anti-CipA antibody (1:100). Binding of FI to *A. baumannii* strains upon NHS

830 incubation was assessed by Western blotting using an anti-FI antibody (1:1,000) **(B)**. Survival

831 of *A. baumannii* strains in human serum **(C and D)**. 5×10^7 cells of *A. baumannii* $\Delta cipA::cipA$

832 ($\square$), $\Delta cipA$ ($\blacktriangle$), and $\Delta cipA::cipA$ E360P ($\blacksquare$) were incubated in increasing amounts of human

833 serum for 2 h at 37 °C, serially diluted and cfu counts determined. CfU counts were related to

834 controls incubated in LB medium instead of serum, for which survival was set at 100%.

835 Shown are results from at least three independent experiments **(C)**. Survival of *A. baumannii*

836 strains at 50% **(D)**. **, $p \leq 0.002$, ****, $p \leq 0.0001$, n.s., no statistical significance, one-way

837 ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%).

838

839 **Fig 8. Molecular mechanism of complement inactivation mediated by CipA (hypothetical)**

840 Schematic representation of the molecular mechanism of complement inactivation by

841 generating a quadripartite complex consisting of CipA, FI, C3b, and FH or CipA, FI, C4b, and

842 C4BP. The figure was created with BioRender.com.

A

CipA WT

CipA Δ Q19-Q144CipA Δ L154-K369CipA Δ Q291-K369CipA Δ A352-K369CipA Δ E360-K369 CipA Δ Q19-Q144CipA Δ L154-K369CipA Δ Q291-K369**B**

alternative pathway

C

classical pathway

D

C-terminus of CipA

CipA mutations	350	360	369
CipA	SQADVLD	MVVEQELVKKPKK	
P367A	SQADVLD	MVVEQELVKKAKK	
E360P	SQADVLD	MVVPQELVKKPKK	
K365A-K369A	SQADVLD	MVVEQELVAAPAA	
Δ L363	SQADVLD	MVVEQE-VKKPKK	
Δ V364	SQADVLD	MVVEQEL-KKKPKK	
Δ P367	SQADVLD	MVVEQELVKK-KK	
Δ L363-V364	SQADVLD	MVVEQE--KKPKK	
Δ V364-K369	SQADVLD	MVVEQEL-----	
Δ L363-K369	SQADVLD	MVVEQE-----	
Δ E362-K369	SQADVLD	MVVEQ-----	
Δ Q361-K369	SQADVLD	MVVE-----	

E

alternative pathway

F

classical pathway

A **B**

A **B** **C** **D** **E**

A **B** **C** **D** **E** **F**

AP

CP/LP

Binding of FI

Formation of quadripartite complex

Cleavage of C3b/C4b

Termination of complement activation